JP2002308895A5 - - Google Patents

Download PDF

Info

Publication number
JP2002308895A5
JP2002308895A5 JP2002026232A JP2002026232A JP2002308895A5 JP 2002308895 A5 JP2002308895 A5 JP 2002308895A5 JP 2002026232 A JP2002026232 A JP 2002026232A JP 2002026232 A JP2002026232 A JP 2002026232A JP 2002308895 A5 JP2002308895 A5 JP 2002308895A5
Authority
JP
Japan
Prior art keywords
angstroms
rays
irradiation
wavelength
copper
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002026232A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002308895A (ja
JP3748536B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2002026232A priority Critical patent/JP3748536B2/ja
Priority claimed from JP2002026232A external-priority patent/JP3748536B2/ja
Publication of JP2002308895A publication Critical patent/JP2002308895A/ja
Priority to US10/637,300 priority patent/US6908906B2/en
Publication of JP2002308895A5 publication Critical patent/JP2002308895A5/ja
Application granted granted Critical
Publication of JP3748536B2 publication Critical patent/JP3748536B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002026232A 2001-02-09 2002-02-04 ピリミジンヌクレオシド誘導体の結晶 Expired - Lifetime JP3748536B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2002026232A JP3748536B2 (ja) 2001-02-09 2002-02-04 ピリミジンヌクレオシド誘導体の結晶
US10/637,300 US6908906B2 (en) 2001-02-09 2003-08-07 Crystalline forms of pyrimidine nucleoside derivative

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001-33128 2001-02-09
JP2001033128 2001-02-09
JP2002026232A JP3748536B2 (ja) 2001-02-09 2002-02-04 ピリミジンヌクレオシド誘導体の結晶

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005230800A Division JP4356998B2 (ja) 2001-02-09 2005-08-09 ピリミジンヌクレオシド誘導体の結晶を含有する医薬

Publications (3)

Publication Number Publication Date
JP2002308895A JP2002308895A (ja) 2002-10-23
JP2002308895A5 true JP2002308895A5 (cg-RX-API-DMAC7.html) 2005-08-18
JP3748536B2 JP3748536B2 (ja) 2006-02-22

Family

ID=18896929

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002026232A Expired - Lifetime JP3748536B2 (ja) 2001-02-09 2002-02-04 ピリミジンヌクレオシド誘導体の結晶
JP2005230800A Expired - Lifetime JP4356998B2 (ja) 2001-02-09 2005-08-09 ピリミジンヌクレオシド誘導体の結晶を含有する医薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005230800A Expired - Lifetime JP4356998B2 (ja) 2001-02-09 2005-08-09 ピリミジンヌクレオシド誘導体の結晶を含有する医薬

Country Status (21)

Country Link
EP (1) EP1364959B1 (cg-RX-API-DMAC7.html)
JP (2) JP3748536B2 (cg-RX-API-DMAC7.html)
KR (1) KR100679904B1 (cg-RX-API-DMAC7.html)
CN (1) CN100408591C (cg-RX-API-DMAC7.html)
AT (1) ATE361929T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002230164B2 (cg-RX-API-DMAC7.html)
BR (2) BRPI0207102A8 (cg-RX-API-DMAC7.html)
CA (1) CA2437994C (cg-RX-API-DMAC7.html)
CY (1) CY1106685T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ303241B6 (cg-RX-API-DMAC7.html)
DE (1) DE60220024T2 (cg-RX-API-DMAC7.html)
DK (1) DK1364959T3 (cg-RX-API-DMAC7.html)
ES (1) ES2286237T3 (cg-RX-API-DMAC7.html)
HU (1) HU229294B1 (cg-RX-API-DMAC7.html)
IL (2) IL157216A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03007123A (cg-RX-API-DMAC7.html)
NZ (1) NZ527393A (cg-RX-API-DMAC7.html)
PT (1) PT1364959E (cg-RX-API-DMAC7.html)
RU (1) RU2256666C2 (cg-RX-API-DMAC7.html)
WO (1) WO2002064609A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200306121B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081419B1 (en) 1999-09-02 2013-08-07 Ibiden Co., Ltd. Printed circuit board and method of manufacturing printed circuit board
CN101232776B (zh) 1999-09-02 2011-04-20 揖斐电株式会社 印刷布线板
GB0526419D0 (en) 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
JP5066737B2 (ja) * 2007-04-06 2012-11-07 大鵬薬品工業株式会社 シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤
US8124593B2 (en) 2007-11-05 2012-02-28 Cyclacel Limited Methods of treatment using sapacitabine
GB0808357D0 (en) * 2008-05-08 2008-06-18 Cyclacel Ltd Process
PL2307002T3 (pl) 2008-06-09 2013-05-31 Cyclacel Ltd Kombinacje sapacytabiny lub cndac z inhibitorami metylotransferazy dna, takimi jak decytabina i prokaina
PL2696878T3 (pl) 2011-04-14 2020-01-31 Cyclacel Limited Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej
ES2880109T3 (es) 2012-03-15 2021-11-23 Celgene Car Llc Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
ES2963057T3 (es) * 2015-03-09 2024-03-25 Grace W R & Co Forma cristalina de ribósido de nicotinamida
EP3727400A4 (en) 2017-12-22 2021-10-20 Elysium Health, Inc. CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
FI105556B (fi) * 1991-09-30 2000-09-15 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten pyrimidiiniukleosidijohdannaisten valmistamiseksi, joilla on kasvaimen vastaista vaikutusta

Similar Documents

Publication Publication Date Title
JP2023145481A5 (cg-RX-API-DMAC7.html)
JP2018024682A5 (cg-RX-API-DMAC7.html)
JP2013538253A5 (cg-RX-API-DMAC7.html)
JP2011168587A5 (cg-RX-API-DMAC7.html)
JP2020511467A5 (cg-RX-API-DMAC7.html)
RU2012138892A (ru) СОЛИ И ПОЛИМОРФЫ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5,-ТЕТРАГИДРО-6Н-АЗЕПИНО[5,4,3-cd]ИНДОЛ-6-ОНА
JP2004524889A5 (cg-RX-API-DMAC7.html)
JP2005527336A5 (cg-RX-API-DMAC7.html)
JP2004188187A5 (cg-RX-API-DMAC7.html)
JP2009502743A5 (cg-RX-API-DMAC7.html)
JP2005526058A5 (cg-RX-API-DMAC7.html)
UY29407A1 (es) Forma cristalina gamma-d del clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmaceuticas que la contienen.
AR029571A1 (es) Nueva forma cristalina beta de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
ATE520406T1 (de) Kristalline form des ibandronat-natriums
RU2222544C1 (ru) Кристалл производного аспартама
JP2007191765A5 (cg-RX-API-DMAC7.html)
CA2522486A1 (en) Bromide and crystals thereof
JP2004510683A5 (cg-RX-API-DMAC7.html)
JP2006502115A5 (cg-RX-API-DMAC7.html)
RU99104300A (ru) Кристаллическая модификация фармацевтического агента
CU23200A3 (es) Sal polimorfica
CA2437994A1 (en) Crystalline forms of pyrimidine nucleoside derivative
PE20090192A1 (es) Sal citrato de 2-hidroxi-3-[5-(morfolin-4-ilmetil)piridin-2-il]1h-indol-5-carbonitrilo
TW200628474A (en) Organic compounds
JP2005505571A5 (cg-RX-API-DMAC7.html)